摘要
由中山医科大学肿瘤医院为负责单位,8个单位组成协作组,对山东医科院药物所研制的卡铂(Carboplatin)进行了Ⅱ期临床研究。受试的各类确诊癌症患者共359例,包括肺癌,头颈癌,妇科癌,睾丸癌等。其中单用卡铂治疗205例,14例获CR,54例获PR,总缓解率31.71％,初治病例106例,单用卡铂其总缓解率为39.6％,以卵巢癌、睾丸癌、小细胞肺癌及初治的鼻咽癌等疗效最为显著。另154例系联合化疗,分别用DDP联合化疗(其他药物种类及剂量相同)作对照,结果证明总缓解率分别为:小细胞肺癌72.5％,睾丸癌80％,卵巢癌45.5％,鼻咽癌58.3％,与相应的PDD联合化疗组对照缓解率均无显著差异(P>0.05),毒付反应对比则胃肠道反应比顺铂联合组为轻(P<0.05),血液毒性无大差异(P>0.05)。结论表明,卡铂有肯定的抗肿瘤活性,其疗效与DDP相当而胃肠道反应较轻,且不需水化而无明显肾毒性,易为患者所耐受。主要毒副反应为骨髓毒性。
Charged by Sun Yat-sen University of medical Sciences Cancer Hospital, 8 hospital joined to for a co-op group and 359 cases of proven malignancies were Studied with Carboplatin. 205 cases were treated with Carboplatin alone, 14 achieved CR, 54 PR, total Response Rate 31.71%, in 106 Previously untreated cases the RR was 39.6% . Ovarian Cancer, Testis Cancer, Small Cell Lung Cancer and previously untreated Nasopharyn-geal Cancer were among the most sensitive ones, 154 cases were treated with Carboplatin combined with other cytostatics, with DDP combination as controls, the response rate of Carboplatin combinations were: SCLC 72.5%, Testis Ca 80%, Ovary Ca 45.5% NPC 58.3% . which were not statistically different from corresponding DDP combinations (P> 0.05) . A comparison of the side effects showed that Carboplatin had less severe G-I toxicities (P<0.05) however, the hematologic toxicities were similar (P>05) Compared with DDP Combinations, In conclusion, Carboplatin showed definite anticancer activity, its efficacy was comparable to DDP with less G-I toxicity, and essentially not nephroto-xic without forced hydration and was well tolerated and accepted by the patients.
出处
《癌症》
SCIE
CAS
CSCD
北大核心
1990年第6期456-461,共6页
Chinese Journal of Cancer
